Lorrain Daniel S.: insider trades.
Lorrain Daniel S. reported 9 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 0 open-market purchases and 5 sales ($611K), across 1 company.
- Transactions
- 9
- Purchases (P)
- 0
- Sales (S)
- 5
- Companies
- 1
- Name as filed
- Lorrain Daniel S.
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | Officer · Chief Scientific Officer | 9 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-07-09 | Contineum Therapeutics, Inc. | S | 25 | $16 | 135,202 | Form 4 |
| 2026-07-09 | Contineum Therapeutics, Inc. | M | 25 | $1.01 | 135,227 | Form 4 |
| 2026-07-08 | Contineum Therapeutics, Inc. | M | 1,015 | $1.01 | 136,217 | Form 4 |
| 2026-07-08 | Contineum Therapeutics, Inc. | S | 1,015 | $16 | 135,202 | Form 4 |
| 2026-07-01 | Contineum Therapeutics, Inc. | S | 2,501 | $16.24 | 135,202 | Form 4 |
| 2026-07-01 | Contineum Therapeutics, Inc. | S | 5,852 | $15.67 | 137,703 | Form 4 |
| 2026-07-01 | Contineum Therapeutics, Inc. | M | 4,183 | $1.01 | 143,555 | Form 4 |
| 2026-06-30 | Contineum Therapeutics, Inc. | S | 28,826 | $16.04 | 139,372 | Form 4 |
| 2026-06-30 | Contineum Therapeutics, Inc. | M | 28,826 | $1.01 | 168,198 | Form 4 |
Questions
What stock did Lorrain Daniel S. buy or sell?
Lorrain Daniel S. reported 9 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 0 open-market purchases and 5 sales ($611K), across 1 company.
Is Lorrain Daniel S. the same person as other filers with this name?
This page covers SEC CIK 1861550 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/lorrain-daniel-s-1861550.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.